These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 11215846)

  • 1. Combined therapy with an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor in heart failure.
    Struckman DR; Rivey MP
    Ann Pharmacother; 2001 Feb; 35(2):242-8. PubMed ID: 11215846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Angiotensin receptor antagonists and ACE inhibitors in heart failure: alternative or combined therapies?].
    Rapezzi C; Perugini E
    Monaldi Arch Chest Dis; 2002 May; 58(1):54-6. PubMed ID: 12693071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination ACE inhibitors and angiotensin II receptor blockers for hypertension.
    Finnegan PM; Gleason BL
    Ann Pharmacother; 2003 Jun; 37(6):886-9. PubMed ID: 12773079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale for the use of combination angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy in heart failure.
    Carson PE
    Am Heart J; 2000 Sep; 140(3):361-6. PubMed ID: 10966531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New competition in the realm of renin-angiotensin axis inhibition; the angiotensin II receptor antagonists in congestive heart failure.
    Martineau P; Goulet J
    Ann Pharmacother; 2001 Jan; 35(1):71-84. PubMed ID: 11197588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha-1 adrenoceptor-angiotensin II type 1 receptor cross-talk and its relevance in clinical medicine.
    Vittorio TJ; Fudim M; Wagman G; Kosmas CE
    Cardiol Rev; 2014; 22(2):51-5. PubMed ID: 23707993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction.
    Savarese G; Edner M; Dahlström U; Perrone-Filardi P; Hage C; Cosentino F; Lund LH
    Int J Cardiol; 2015 Nov; 199():415-23. PubMed ID: 26247798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin antagonism in patients with heart failure: ACE inhibitors, angiotensin receptor antagonists or both?
    Cruden NL; Newby DE
    Am J Cardiovasc Drugs; 2004; 4(6):345-53. PubMed ID: 15554719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
    Schindler C
    Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    Weir RA; McMurray JJ; Puu M; Solomon SD; Olofsson B; Granger CB; Yusuf S; Michelson EL; Swedberg K; Pfeffer MA;
    Eur J Heart Fail; 2008 Feb; 10(2):157-63. PubMed ID: 18242128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Review of randomized trials of angiotensin receptor blockers in the treatment of patients with congestive heart failure].
    Rakugi H; Ogihara T
    Nihon Rinsho; 2001 Oct; 59(10):2051-61. PubMed ID: 11676153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic role of angiotensin II receptor blockers in the treatment of heart failure.
    Manohar P; Piña IL
    Mayo Clin Proc; 2003 Mar; 78(3):334-8. PubMed ID: 12630586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels.
    Komine N; Khang S; Wead LM; Blantz RC; Gabbai FB
    Am J Kidney Dis; 2002 Jan; 39(1):159-64. PubMed ID: 11774115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
    Cohn JN; Tognoni G;
    N Engl J Med; 2001 Dec; 345(23):1667-75. PubMed ID: 11759645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on therapy for heart failure.
    DiBianco R
    Am J Med; 2003 Oct; 115(6):480-8. PubMed ID: 14563505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study.
    Krum H; Shi H; Pitt B; McMurray J; Swedberg K; van Veldhuisen DJ; Vincent J; Pocock S; Zannad F;
    Circ Heart Fail; 2013 Jul; 6(4):711-8. PubMed ID: 23625945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renin Angiotensin Aldosterone System Blockade: Little to No Rationale for ACE Inhibitor and ARB Combinations.
    Holdiness A; Monahan K; Minor D; de Shazo RD
    Am J Med; 2011 Jan; 124(1):15-9. PubMed ID: 21187182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin II receptor blockers in heart failure.
    Patterson JH
    Pharmacotherapy; 2003 Feb; 23(2):173-82. PubMed ID: 12587806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.